Drug Trial Radar · NCT07909031
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
219
Planned (sponsor's estimate)
Start
Oct 21, 2026
Primary completion
Oct 2028
Study completion Jan 2029
Sponsor
- Lead sponsor
- Crescent Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.
Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
- Gastric/GEJ
- Biliary Tract Cancer (BTC)
- Esophageal Squamous Cell Carcinoma (ESCC)
- Ovarian Cancer
- Endometrial Cancer
- Cervical Cancer Metastatic
- Non-small Cell Lung Cancer (NSCLC)
Interventions
CR-002Drug
Intravenous Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Dose Escalation - incidence and nature of dose-limiting toxicitiesTime frame: From the first dose of study drug up until approximately 1 month
- Part 1: Dose Escalation - characterization of the maximum tolerated dose, if applicableTime frame: From the first dose of study drug up until approximately 1 month
- All Parts - incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse eventsTime frame: From the first dose of study drug until 90 days after the last dose of study drug
- All Parts - incidence and severity of TEAEs leading to dose modificationsTime frame: From the first dose of study drug until 90 days after the last dose of study drug
- All Parts - incidence and severity of TEAEs leading to treatment discontinuationTime frame: From the first dose of study drug until 90 days after the last dose of study drug
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Clinical Study Site
Austin, Texas · Recruiting
Clinical Study Site
Dallas, Texas · Recruiting
Clinical Study Site
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.